4-[(4-acetylphenyl)amino]benzoic acid | 852927-10-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[(4-acetylphenyl)amino]benzoic acid
• 英文别名: 4-(4-acetylanilino)benzoic acid
• CAS: 852927-10-7
• 化学式: C₁₅H₁₃NO₃
• 分子量: 255.273
• InChiKey: NDXFEWROUZQZHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-[(4-acetylphenyl)amino]benzoic acid methyl ester 在 potassium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 以52%的产率得到4-[(4-acetylphenyl)amino]benzoic acid
  参考文献：
  名称：

  Development of Potent and Selective Inhibitors of Aldo–Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on N-Phenyl-Aminobenzoates and Their Structure–Activity Relationships

  摘要：

  Aldo-keto reductase 1C3 (AKR1C3; type 5 17 beta-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated in the intratumoral biosynthesis of testosterone and 5 alpha-dihydrotestosterone. Selective AKR1C3 inhibitors are required because compounds should not inhibit the highly related AKR1C1 and AKR1C2 isoforms which are involved in the inactivation of Sa-dihydrotestosterone. NSAIDs, N-phenylanthranilates in particular, are potent but nonselective AKR1C3 inhibitors. Using flufenamic acid, 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid, as lead compound, five classes of structural analogues were synthesized and evaluated for AKR1C3 inhibitory potency and selectivity. Structure-activity relationship (SAR) studies revealed that a meta-carboxylic acid group relative to the amine conferred pronounced AKR1C3 selectivity without loss of potency, while electron withdrawing groups on the phenylamino B-ring were optimal for AKR1C3 inhibition. Lead compounds did not inhibit COX-1 or COX-2 but blocked the AKR1C3 mediated production of testosterone in LNCaP-AKR1C3 cells. These compounds offer promising leads toward new therapeutics for CRPC.

  DOI：

  10.1021/jm201547v

文献信息

• Nitroso derivatives of diphenylamine
  申请人：Lardy Claude

  公开号：US20070123586A1

  公开（公告）日：2007-05-31

  The invention relates to a compound of the formula I in which: R 1 represents, independently of each other, a halogen atom; an aliphatic hydrocarbon-based group optionally substituted and/or optionally interrupted by one or more oxygen or sulfur atoms; a nitro group; a cyano group; an amino group; a mono- or dialkylamino group; an alkylcarbonyl group; a carboxyl group; an alkylcarbonylamino group; an alkylsulfonyl group; R 2 represents, independently of each other, a cyano group; a hydroxyl group, an alkylcarbonyl group; a carboxyl group; an alkoxycarbonyl group; an unsubstituted amide group; or a linear or branched alkyl group substituted by a cyano, hydroxyl, carboxyl, alkoxycarbonyl or unsubstituted amide group; i and j independently being 1 to 5, with the exclusion of the compound for which i and j=1 and R 1 =carboxyl and R 2 =alkoxycarbonyl or R 1 =CF 3 and R 2 =carboxyl, and also the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions.

  本发明涉及一种具有公式I的化合物，其中：R1分别表示卤素原子；一种基于脂肪族的羟基烃基团，可选地被一个或多个氧或硫原子取代和/或中断；硝基基团；氰基团；氨基团；一种单烷基或二烷基氨基团；烷基羰基基团；羧基团；烷基羰基氨基基团；烷基磺酰基基团；R2分别表示氰基团；羟基团；烷基羰基基团；羧基团；烷氧羰基基团；未取代酰胺基团；或线性或支链烷基团，被氰基，羟基，羧基，烷氧羰基或未取代酰胺基团取代；i和j分别独立地为1到5，除了i和j=1且R1=羧基和R2=烷氧羰基或R1=CF3和R2=羧基的化合物之外，还包括其药学上可接受的衍生物，盐，溶剂和立体异构体，包括所有比例的混合物。
• Diphenylamine derivatives
  申请人：Lardy Claude

  公开号：US20070129433A1

  公开（公告）日：2007-06-07

  The invention relates to compounds of the formula (I) in which: i and j=1; R 1 is in position 3 or 4 on the phenyl ring and represents a cyano group, an alkoxy group substituted by halogen, a thioalkyl group, an alkylcarbonyl group or an alkylsulfonyl group; and R 2 represents a carboxyl group, an aikoxycarbonyl group, an alkylcarbonyl group, an unsubstituted amide group or a linear or branched alkyl group substituted by a cyano, hydroxyl, cabboxyl, aikoxycarbonyl or unsubstituted amide group; and also the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions.

  本发明涉及式(I)的化合物，其中：i和j=1；R1位于苯环上的3或4位置，并表示氰基，被卤素取代的烷氧基，硫代烷基，烷基羰基基团或烷基磺酰基团；R2表示羧基，烷氧羰基基团，烷基羰基基团，未取代酰胺基团或被氰基，羟基，羧基，烷氧羰基或未取代酰胺基团取代的线性或支链烷基；以及其药学上可接受的衍生物，盐，溶剂合物和立体异构体，包括所有比例的混合物。
• DIPHENYLAMINE DERIVATIVES
  申请人：Merk Patent Gmbh

  公开号：EP1687253A2

  公开（公告）日：2006-08-09
• [EN] DIPHENYLAMINE DERIVATIVES<br/>[FR] DERIVES DE IPHENYLAMINE
  申请人：MERCK PATENT GMBH

  公开号：WO2005051888A2

  公开（公告）日：2005-06-09

  The invention relates to compounds of the formula (I) in which: i and j=1; R1 is in position 3 or 4 on the phenyl ring and represents a cyano group, an alkoxy group substituted by halogen, a thioalkyl group, an alkylcarbonyl group or an alkylsulfonyl group; and R2 represents a carboxyl group, an aikoxycarbonyl group, an alkylcarbonyl group, an unsubstituted amide group or a linear or branched alkyl group substituted by a cyano, hydroxyl, carboxyl, aikoxycarbonyl or unsubstituted amide group; and also the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all propor­tions.
• Development of Potent and Selective Inhibitors of Aldo–Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on <i>N</i>-Phenyl-Aminobenzoates and Their Structure–Activity Relationships
  作者：Adegoke O. Adeniji、Barry M. Twenter、Michael C. Byrns、Yi Jin、Mo Chen、Jeffrey D. Winkler、Trevor M. Penning

  DOI：10.1021/jm201547v

  日期：2012.3.8

  Aldo-keto reductase 1C3 (AKR1C3; type 5 17 beta-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated in the intratumoral biosynthesis of testosterone and 5 alpha-dihydrotestosterone. Selective AKR1C3 inhibitors are required because compounds should not inhibit the highly related AKR1C1 and AKR1C2 isoforms which are involved in the inactivation of Sa-dihydrotestosterone. NSAIDs, N-phenylanthranilates in particular, are potent but nonselective AKR1C3 inhibitors. Using flufenamic acid, 2-[3-(trifluoromethyl)phenyl]amino}benzoic acid, as lead compound, five classes of structural analogues were synthesized and evaluated for AKR1C3 inhibitory potency and selectivity. Structure-activity relationship (SAR) studies revealed that a meta-carboxylic acid group relative to the amine conferred pronounced AKR1C3 selectivity without loss of potency, while electron withdrawing groups on the phenylamino B-ring were optimal for AKR1C3 inhibition. Lead compounds did not inhibit COX-1 or COX-2 but blocked the AKR1C3 mediated production of testosterone in LNCaP-AKR1C3 cells. These compounds offer promising leads toward new therapeutics for CRPC.